These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Gould KL; Martucci JP; Goldberg DI; Hess MJ; Edens RP; Latifi R; Dudrick SJ Circulation; 1994 Apr; 89(4):1530-8. PubMed ID: 8149518 [TBL] [Abstract][Full Text] [Related]
4. [Improved coronary vasodilator capacity by drug lipid lowering therapy in patients in the early stage of coronary atherosclerosis with reduced coronary reserves and moderate LDL hypercholesteremia]. Baller D; Gleichmann U; Notohamiprodjo G; Weise R; Holzinger J; Montanus H; Betker S; Lehmann J Z Kardiol; 1998; 87 Suppl 2():136-44. PubMed ID: 9827472 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of progression and regression of coronary artery disease by PET related to treatment intensity and clinical events at long-term follow-up. Sdringola S; Loghin C; Boccalandro F; Gould KL J Nucl Med; 2006 Jan; 47(1):59-67. PubMed ID: 16391188 [TBL] [Abstract][Full Text] [Related]
6. Influence on lifestyle measures and five-year coronary risk by a comprehensive lifestyle intervention programme in patients with coronary heart disease. Vestfold Heartcare Study Group Eur J Cardiovasc Prev Rehabil; 2003 Dec; 10(6):429-37. PubMed ID: 14671465 [TBL] [Abstract][Full Text] [Related]
7. New concepts and paradigms in cardiovascular medicine: the noninvasive management of coronary artery disease. Gould KL Am J Med; 1998 Jun; 104(6A):2S-17S. PubMed ID: 9684847 [TBL] [Abstract][Full Text] [Related]
8. The effect of high-protein diets on coronary blood flow. Fleming RM Angiology; 2000 Oct; 51(10):817-26. PubMed ID: 11108325 [TBL] [Abstract][Full Text] [Related]
11. A strategy to arrest and reverse coronary artery disease: a 5-year longitudinal study of a single physician's practice. Esselstyn CB; Ellis SG; Medendorp SV; Crowe TD J Fam Pract; 1995 Dec; 41(6):560-8. PubMed ID: 7500065 [TBL] [Abstract][Full Text] [Related]
12. High prevalence of myocardial perfusion abnormalities on positron emission tomography in asymptomatic persons with a parent or sibling with coronary artery disease. Sdringola S; Patel D; Gould KL Circulation; 2001 Jan; 103(4):496-501. PubMed ID: 11157712 [TBL] [Abstract][Full Text] [Related]
13. Frequency and clinical implications of fluid dynamically significant diffuse coronary artery disease manifest as graded, longitudinal, base-to-apex myocardial perfusion abnormalities by noninvasive positron emission tomography. Gould KL; Nakagawa Y; Nakagawa K; Sdringola S; Hess MJ; Haynie M; Parker N; Mullani N; Kirkeeide R Circulation; 2000 Apr; 101(16):1931-9. PubMed ID: 10779459 [TBL] [Abstract][Full Text] [Related]
14. Serum cholesterol, lifestyle, working capacity and quality of life in patients with coronary artery disease. Experiences from a hospital-based secondary prevention programme. Carlsson R Scand Cardiovasc J Suppl; 1998; 50():1-20. PubMed ID: 9802147 [TBL] [Abstract][Full Text] [Related]
15. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910 [TBL] [Abstract][Full Text] [Related]
16. Effect of short-term cardiovascular conditioning and low-fat diet on myocardial blood flow and flow reserve. Czernin J; Barnard RJ; Sun KT; Krivokapich J; Nitzsche E; Dorsey D; Phelps ME; Schelbert HR Circulation; 1995 Jul; 92(2):197-204. PubMed ID: 7600651 [TBL] [Abstract][Full Text] [Related]
17. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751 [TBL] [Abstract][Full Text] [Related]